Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5AP | P20292 | 13/20 | 0.38 |
| ▸ | FEN1 | P39748 | 13/20 | 0.38 |
| ▸ | TDO2 | P48775 | 2/20 | 0.38 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.37 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.34 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.33 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.33 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.33 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2306298 | 0.89 | TDO2 (0.39) | ALOX5APFEN1TDO2HCRTR1 | |
| SCHEMBL2307068 | 0.89 | TDO2 (0.40) | ALOX5APFEN1TDO2 | |
| SCHEMBL2303196 | 0.88 | PTGS2 (0.44) | ALOX5APFEN1TDO2PTGS2PTGS1 | |
| SCHEMBL2299608 | 0.87 | ALOX5 (0.39) | ALOX5APFEN1TDO2HCRTR1 | |
| SCHEMBL2299338 | 0.86 | HCRTR1 (0.39) | ALOX5APFEN1TDO2PTGS2HCRTR1 | |
| SCHEMBL2297980 | 0.86 | PKM (0.36) | TDO2PTGS2 | |
| SCHEMBL2303530 | 0.84 | PDK2 (0.34) | TDO2 | |
| SCHEMBL2300754 | 0.84 | ALDH1A1 (0.35) | ALOX5APFEN1TDO2 | |
| SCHEMBL2302675 | 0.84 | ALOX5 (0.42) | PTGS2PTGS1 | |
| SCHEMBL14119484 | 0.84 | HTR6 (0.39) | TDO2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9034888-B2 | Substituted 2-imidazolidones and analogs | UNIVERSITE LAVAL (CA) | 2015-05-19 | — | — | US | disclosed |
| EP-2536693-A1 | SUBSTITUTED 2-IMIDAZOLIDONES AND ANALOGS | Université Laval (CA) | 2012-12-26 | — | — | EP | disclosed |
| US-20120309777-A1 | SUBSTITUTED 2-IMIDAZOLIDONES AND ANALOGS | UNIVERSITE LAVAL (CA) | 2012-12-06 | — | — | US | disclosed |
| WO-2011100840-A1 | SUBSTITUTED 2-IMIDAZOLIDONES AND ANALOGS | UNIVERSITé LAVAL (CA) | 2011-08-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120309777-A1 | SUBSTITUTED 2-IMIDAZOLIDONES AND ANALOGS | CCNY, RPS4Y1, TPX2 | ALOX5AP 4772/4885FEN1 3053/4885TDO2 3925/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.